Immune-related biomarkers for diagnosis/prognosis and therapy monitoring of cutaneous melanoma

References

• Kalialis LV, Drzewiecki KT, Klyver H. Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res.5, 275–282 (2009).
   Google Scholar
• Rigel DS. Trends in dermatology: melanoma incidence. Arch. Dermatol.146(3), 318 (2010).
   PubMedGoogle Scholar
• Bos JD. Skin Immune System: Cutaneous Immunology and Clinical Immunodermatology (3rd Edition). CRC Press, NY, USA, 3–13 (2005).
   Google Scholar
• Woods GM, Malley RC, Muller HK. The skin immune system and the challenge of tumor immunosurveillance. Eur. J. Dermatol.15(2), 63–69 (2005).
   PubMed Web of Science ®Google Scholar
• Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol.25, 267–296 (2007).
   PubMed Web of Science ®Google Scholar
• Reiman JM, Kmieciak M, Manjili MH, Knutson KL. Tumor immunoediting and immunosculpting pathways to cancer progression. Semin. Cancer Biol.17(4), 275–287 (2007).
   PubMed Web of Science ®Google Scholar
• Zattra E, Fortina AB, Bordignon M, Piaserico S, Alaibac M. Immunosuppression and melanocyte proliferation. Melanoma Res.19(2), 63–68 (2009).
   PubMed Web of Science ®Google Scholar
• Gajewski TF. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin. Cancer Res.13(18 Pt 1), 5256–5261 (2007).
   PubMed Web of Science ®Google Scholar
• Wang E, Marincola FM. cDNA arrays and the enigma of melanoma immune responsiveness. Cancer J.7(1), 16–24 (2001).
   PubMed Web of Science ®Google Scholar
• Ilkovitch D, Lopez DM. Immune modulation by melanoma-derived factors. Exp. Dermatol.17(12), 977–985 (2008).
   PubMedGoogle Scholar
• Loser K, Brzoska T, Oji V et al. The neuropeptide α-melanocyte-stimulating hormone is critically involved in the development of cytotoxic CD8+ T cells in mice and humans. PLoS ONE5(2), e8958 (2010).
   PubMed Web of Science ®Google Scholar
• Gould Rothberg BE, Bracken MB, Rimm DL. Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J. Natl Cancer Inst.101(7), 452–474 (2009).
   PubMedGoogle Scholar
• Staquicini FI, Tandle A, Libutti SK et al. A subset of host B-lymphocytes control melanoma metastasis through a MCAM/MUC18-dependent interaction: evidence from mice and humans. Cancer Res.68(20), 8419–8428 (2008).
   PubMed Web of Science ®Google Scholar
• Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer2, 161–174 (2002).
   PubMed Web of Science ®Google Scholar
• Väisänen AH, Kallioinen M, Turpeenniemi-Hujanen T. Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma. Hum. Pathol.39(3), 377–385 (2008).
   PubMedGoogle Scholar
• Hillen F, van de Winkel A, Creytens D, Vermeulen AH, Griffioen AW. Proliferating endothelial cells, but not microvessel density, are a prognostic parameter in human cutaneous melanoma. Melanoma Res.16(5), 453–457 (2006).
   PubMed Web of Science ®Google Scholar
• Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW. Immunohistochemical characteristics of melanoma. J. Cutan. Pathol.35(5), 433–444 (2008).
   PubMed Web of Science ®Google Scholar
• Smalley KS, Contractor R, Haass NK et al. Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels. Br. J. Cancer96(3), 445–449 (2007).
   PubMed Web of Science ®Google Scholar
• Alonso SR, Ortiz P, Polla’n M et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles – a tissue microarray-based study. Am. J. Pathol.164(1), 193–203 (2004).
   PubMed Web of Science ®Google Scholar
• Hilliard NJ, Krahl D, Sellheyer K. p16 expression differentiates between desmoplastic Spitz nevus and desmoplastic melanoma. J. Cutan. Pathol.36(7), 753–759 (2009).
   PubMedGoogle Scholar
• Sanki A, Li W, Colman M, Karim RZ, Thompson JF, Scolyer RA. Reduced expression of p16 and p27 is correlated with tumour progression in cutaneous melanoma. Pathology39(6), 551–557 (2007).
   PubMed Web of Science ®Google Scholar
• Mihic-Probst D, Kuster A, Kilgus S et al. Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma. Int. J. Cancer121(8), 1764–1770 (2007).
   PubMedGoogle Scholar
• Ladányi A. [Function and prognostic significance of immune cells infiltrating human tumors]. Magy Onkol.48(1), 49–56 (2004).
   PubMedGoogle Scholar
• Ladányi A, Mohos A, Somlai B et al. FOXP3+ cell density in primary tumor has no prognostic impact in patients with cutaneous malignant melanoma. Pathol. Oncol. Res.16(3), 303–309 (2010).
   PubMedGoogle Scholar
• Kiss J, Tímár J, Somlai B et al. Association of microvessel density with infiltrating cells in human cutaneous malignant melanoma. Pathol. Oncol. Res.13(1), 21–31 (2007).
   PubMedGoogle Scholar
• Ribas A, Kirkwood JM, Atkins MB et al. Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma. J. Transl. Med.7, 68 (2009).
   PubMed Web of Science ®Google Scholar
• Zhao F, Falk C, Osen W, Kato M, Schadendorf D, Umansky V. Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma. Clin. Cancer Res.15(13), 4382–4390 (2009).
   PubMedGoogle Scholar
• Lee TH, Cho YH, Lee JD, Yang WI, Shin JL, Lee MG. Enhanced antitumor effect of dendritic cell based immunotherapy after intratumoral injection of radionuclide Ho-166 against B16 melanoma. Immunol. Lett.106(1), 19–26 (2006).
   PubMed Web of Science ®Google Scholar
• Costache M, Simionescu O, Sajin M et al. Apoptosis in cutaneous melanomas. Rom. J. Morphol. Embryol.48(4), 343–347 (2007).
   PubMedGoogle Scholar
• Simionescu O, Dumitrescu D, Costache M, Blum A. Dermatoscopy of an invasive melanoma on the upper lip shows possible association with Laugier-Hunziker syndrome. J. Am. Acad. Dermatol.59(5), 105–108 (2008).
   Google Scholar
• Ladányi A, Kiss J, Somlai B et al. Density of DC-LAMP+ mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol. Immunother.56(9), 1459–1469 (2007).
   PubMed Web of Science ®Google Scholar
• Breslow A. Thickness, cross-sectional areas, and depth of invasion in the prognosis of cutaneous melanoma. Ann. Surg.172, 902–908 (1970).
   PubMed Web of Science ®Google Scholar
• Anger M, Friedhofer H, Fukutaki MF, Ferreira MC, Landman G. Primary cutaneous melanoma: an 18-year study. Clinics (Sao Paulo)65(3), 257–263 (2010).
   PubMedGoogle Scholar
• Balch CM, Soong SJ, Gershenwald JE et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol.19(16), 3622–3634 (2001).
   PubMed Web of Science ®Google Scholar
• Donga C and Robertson GP. Immunoediting of leukocyte functions within the tumor microenvironment promotes cancer metastasis development. Biorheology46(4), 265–279 (2009).
   PubMedGoogle Scholar
• Degenhardt Y, Huang J, Greshock J et al. Distinct MHC gene expression patterns during progression of melanoma. Genes Chromosomes Cancer49(2), 144–154 (2010).
   PubMed Web of Science ®Google Scholar
• Dissemond J, Kothen T, Mörs J et al. Downregulation of tapasin expression in progressive human malignant melanoma. Arch. Dermatol. Res.295(2), 43–49 (2003).
   PubMed Web of Science ®Google Scholar
• Martins I, Sylla K, Deshayes F et al. Coexpression of major histocompatibility complex class II with chemokines and nuclear NFκB p50 in melanoma: a rational for their association with poor prognosis. Melanoma Res.19(4), 226–237 (2009).
   PubMed Web of Science ®Google Scholar
• Quereux G, Pandolfino MC, Knol AC et al. Tissue prognostic markers for adoptive immunotherapy in melanoma. Eur. J. Dermatol.17(4), 295–301 (2007).
   PubMedGoogle Scholar
• Fecker LF, Geilen CC, Tchernev G et al. Loss of proapoptotic bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis. J. Invest. Dermatol.126, 1366–1371 (2006).
   PubMed Web of Science ®Google Scholar
• Ständer S, Schwarz T. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is expressed in normal skin and cutaneous inflammatory diseases, but not in chronically UV-exposed skin and non-melanoma skin cancer. Am. J. Dermatopathol.27(2), 116–121 (2005).
   PubMedGoogle Scholar
• Nguyen T, Thomas W, Zhang XD, Gray C, Hersey P. Immunologically-mediated tumor cell apoptosis: the role of TRAIL in T cell and cytokine-mediated responses to melanoma. Forum (Genova)10(3), 243–252 (2000).
   PubMedGoogle Scholar
• Wu JJ, Zhang XD, Gillespie S, Hersey P. Selection for TRAIL resistance results in melanoma cells with high proliferative potential. FEBS Lett.579(9), 1940–1944 (2005).
   PubMedGoogle Scholar
• Zhuang L, Lee CS, Scolyer RA et al. Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand. Hum. Pathol.37(10), 1286–1294 (2006).
   PubMed Web of Science ®Google Scholar
• Bron LP, Scolyer RA, Thompson JF, Hersey P. Histological expression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in human primary melanoma. Pathology36(6), 561–565 (2004).
   PubMed Web of Science ®Google Scholar
• Logozzi M, De Milito A, Lugini L et al. High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS ONE4(4), e5219 (2009).
   PubMed Web of Science ®Google Scholar
• Lewis TB, Robison JE, Bastien R et al. Molecular classification of melanoma using real-time quantitative reverse transcriptase-polymerase chain reaction. Cancer104(8), 1678–1686 (2005).
   PubMedGoogle Scholar
• García-Gutiérrez M, Toussaint-Caire S, González-Sánchez P, Ortiz-Hidalgo C. Multiple desmoplastic cellular neurothekeomas localized to the face of a 16-year-old boy. Am. J. Dermatopathol.32(5), 509–513 (2010).
   PubMedGoogle Scholar
• Kazakov DV, Kutzner H, Rütten A et al. The anti-MAGE antibody B57 as a diagnostic marker in melanocytic lesions. Am. J. Dermatopathol.26(2), 102–107 (2004).
   PubMedGoogle Scholar
• Zhu X, Asa SL, Ezzat S. Genetic and epigenetic mechanisms down-regulate FGF receptor 2 to induce melanoma-associated antigen A in breast cancer. Am. J. Pathol.176(5), 2333–2343 (2010).
   PubMedGoogle Scholar
• Zhang S, Zhou X, Yu H, Yu Y. Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines. BMC Cancer10, 163 (2010).
   PubMed Web of Science ®Google Scholar
• Paul AK, Ciesielski MJ, Sajjad M et al. Expression of HMP/AN2, a melanoma associated antigen, in murine cerebral gliomas: potential for radioimmunotargeting. J. Neurooncol.94, 21–30 (2009).
   PubMedGoogle Scholar
• Liu F, Killian JK, Yang M et al. Epigenomic alterations and gene expression profiles in respiratory epithelia exposed to cigarette smoke condensate. Oncogene29(25), 3650–3664 (2010).
   PubMed Web of Science ®Google Scholar
• Vourc’h-Jourdain M, Volteau C, Nguyen JM, Khammari A, Dreno B. Melanoma gene expression and clinical course. Arch. Dermatol. Res.301(9), 673–679 (2009).
   PubMedGoogle Scholar
• Neagu M, Constantin C, Manda G, Margaritescu I. Biomarkers of metastatic melanoma. Biomarkers Med.3(1), 71–89 (2009).
   PubMed Web of Science ®Google Scholar
• Ménard C, Ghiringhelli F, Roux S et al. CTLA-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab? Clin. Cancer Res.14(16), 5242–5249 (2008).
   PubMedGoogle Scholar
• Hernberg M, Mattila PS, Rissanen M et al. The prognostic role of blood lymphocyte subset distribution in patients with resected high-risk primary or regionally metastatic melanoma. J. Immunother.30(7), 773–779 (2007).
   PubMedGoogle Scholar
• Casado JG, Soto R, DelaRosa O et al. CD8 T cells expressing NK associated receptors are increased in melanoma patients and display an effector phenotype. Cancer Immunol. Immunother.54(12), 1162–1171 (2005).
   PubMed Web of Science ®Google Scholar
• Campillo JA, Martínez-Escribano JA, Moya-Quiles MR et al. Natural killer receptors on CD8 T cells and natural killer cells from different HLA-C phenotypes in melanoma patients. Clin. Cancer Res.12(16), 4822–4831 (2006).
   PubMedGoogle Scholar
• Avogadri F, Yuan J, Yang A, Schaer D, Wolchok JD. Modulation of CTLA-4 and GITR for cancer immunotherapy. Curr. Top. Microbiol. Immunol. DOI: 10.1007/82_2010_49 (2010) (Epub ahead of print).
   Google Scholar
• Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol.22, 531–562 (2004).
   PubMed Web of Science ®Google Scholar
• Fehérvari Z, Sakaguchi S. CD4+ Tregs and immune control. J. Clin. Invest.114(9), 1209–1217 (2004).
   PubMed Web of Science ®Google Scholar
• Baumgartner J, Wilson C, Palmer B, Richter D, Banerjee A, McCarter M. Melanoma induces immunosuppression by up-regulating FOXP3+ regulatory T cells. J. Surg. Res.141(1), 72–77 (2007).
   PubMed Web of Science ®Google Scholar
• Clark RA, Kupper TS. IL-15 and dermal fibroblasts induce proliferation of natural regulatory T cells isolated from human skin. Blood109(1), 194–202 (2007).
   PubMedGoogle Scholar
• Vence L, Palucka AK, Fay JW et al. Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA18(2), 59–70 (2007).
   Google Scholar
• McCarter MD, Baumgartner J, Escobar GA et al. Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients. Ann. Surg. Oncol.14(10), 2854–2860 (2007).
   PubMed Web of Science ®Google Scholar
• Cesana GC, DeRaffele G, Cohen S et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J. Clin. Oncol.24(7), 1169–1177 (2006).
   PubMed Web of Science ®Google Scholar
• Sutmuller RP, van Duivenvoorde LM, van Elsas A et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med.194(6), 823–832 (2001).
   PubMed Web of Science ®Google Scholar
• Nakai N, Katoh N, Kitagawa T, Ueda E, Takenaka H, Kishimoto S. Immunoregulatory T cells in the peripheral blood of melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination. J. Dermatol. Sci.54(1), 31–37 (2009).
   PubMedGoogle Scholar
• Stockis J, Fink W, François V et al. Comparison of stable human Treg and Th clones by transcriptional profiling. Eur. J. Immunol.39(3), 869–882 (2009).
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Ménard C, Terme M et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner. J. Exp. Med.202(8), 1075–1085 (2005).
   PubMed Web of Science ®Google Scholar
• Konjevic G, Mirjacic Martinovic K, Jurisic V, Babovic N, Spuzic I. Biomarkers of suppressed natural killer (NK) cell function in metastatic melanoma: decreased NKG2D and increased CD158a receptors on CD3-CD16+ NK cells. Biomarkers14(4), 258–270 (2009).
   PubMed Web of Science ®Google Scholar
• Frederiksen KS, Lundsgaard D, Freeman JA et al. IL-21 induces in vivo immune activation of NK cells and CD8+ T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol. Immunother.57(10), 1439–1449 (2008).
   PubMed Web of Science ®Google Scholar
• Konjevic G, Jovic V, Vuletic A, Radulovic S, Jelic S, Spuzic I. CD69 on CD56+ NK cells and response to chemoimmunotherapy in metastatic melanoma. Eur. J. Clin. Invest.37(11), 887–960 (2007).
   PubMedGoogle Scholar
• Guillot B, Portalès P, Thanh AD et al. The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-α treatment. Br. J. Dermatol.152(4), 690–696 (2005).
   PubMed Web of Science ®Google Scholar
• Debenedictis C, Joubeh S, Zhang G, Barria M, Ghohestani RF. Immune functions of the skin. Clin. Dermatol.19, 573–585 (2001).
   PubMed Web of Science ®Google Scholar
• Baumgartner JM, Gonzalez R, Lewis KD et al. Increased survival from stage IV melanoma associated with fewer regulatory T cells. J. Surg. Res.154(1), 13–20 (2009).
   PubMedGoogle Scholar
• Charles J, Di Domizio J, Salameire D et al. Characterization of circulating dendritic cells in melanoma: role of CCR6 in plasmacytoid dendritic cell recruitment to the tumor. J. Invest. Dermatol.130(6), 1646–1656 (2010).
   PubMedGoogle Scholar
• Sabatino M, Stroncek DF, Klein H, Marincola FM, Wang E. Stem cells in melanoma development. Cancer Lett.279(2), 119–125 (2009).
   PubMedGoogle Scholar
• La Porta C. Cancer stem cell: lessons from melanoma. Stem Cell Rev. Rep.5, 61–65 (2009).
   PubMed Web of Science ®Google Scholar
• Deichmann M, Thome M, Egner U, Hartschuh W, Kurzen H. The chemoresistance gene ABCG2 (MXR/BCRP1/ABCP1) is not expressed in melanomas but in single neuroendocrine carcinomas of the skin. J. Cutan. Pathol.32(7), 467–473 (2005).
   PubMed Web of Science ®Google Scholar
• Chen KG, Szakács G, Annereau JP et al. Principal expression of two mRNA isoforms (ABCB 5α and ABCB 5β) of the ATP-binding cassette transporter gene ABCB 5 in melanoma cells and melanocytes. Pigment Cell Res.18(2), 102–112 (2005).
   PubMedGoogle Scholar
• Schatton T, Murphy GF, Frank NY et al. Identification of cells initiating human melanomas. Nature451(7176), 345–349 (2008).
   PubMed Web of Science ®Google Scholar
• Schatton T, Schütte U, Frank NY et al. Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res.70(2), 697–708 (2010).
   PubMed Web of Science ®Google Scholar
• Fusi A, Ochsenreither S, Busse A, Rietz A, Keilholz U. Expression of the stem cell marker nestin in peripheral blood of patients with melanoma. Br. J. Dermatol.163(1), 107–114 (2010).
   PubMed Web of Science ®Google Scholar
• Lugovic L, Situm M, Buljan M, Poduje S, Sebetic K. Results of the determination of serum markers in patients with malignant melanoma. Coll. Antropol.31(Suppl. 1), 7–11 (2007).
   PubMedGoogle Scholar
• Garnier JP, Letellier S, Cassinat B et al. Clinical value of combined determination of plasma L-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma. Eur. J. Cancer43(4), 816–821 (2007).
   PubMedGoogle Scholar
• Faries MB, Gupta RK, Ye X et al. A comparison of 3 tumor markers (MIA, TA90IC, S100B) in stage III melanoma patients. Cancer Invest.25(5), 285–293 (2007).
   PubMed Web of Science ®Google Scholar
• Soubrane C, Rixe O, Meric JB, Khayat D, Mouawad R. Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study. Melanoma Res.15(3), 199–204 (2005).
   PubMed Web of Science ®Google Scholar
• Tas F, Oguz H, Argon A et al. The value of serum levels of IL-6, TNF-α, and erythropoietin in metastatic malignant melanoma: serum IL-6 level is a valuable prognostic factor at least as serum LDH in advanced melanoma. Med. Oncol.22(3), 241–246 (2005).
   PubMedGoogle Scholar
• Balch CM, Gershenwald JE, Soong S-J et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol.27, 6199–6206 (2009).
   PubMed Web of Science ®Google Scholar
• Gupta RK, Cochran AJ, Hsueh EC, Trocha SD, Morton DL. Melanoma (Section 3L). In: Guidelines for the Use of Tumor Markers in Malignant Melanoma. National Academy of Clinical Biochemistry, Washington, DC, USA 1–42 (2005).
   Google Scholar
• Botella-Estrada R, Escudero M, O’Connor JE et al. Cytokine production by peripheral lymphocytes in melanoma. Eur. Cytokine Netw.16(1), 47–55 (2005).
   PubMed Web of Science ®Google Scholar
• Yurkovetsky ZR, Kirkwood JM, Edington HD et al. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-α2b. Clin. Cancer Res.13(8), 2422–2428 (2007).
   PubMed Web of Science ®Google Scholar
• Schwinn N, Vokhminova D, Sucker A et al. Interferon-γ down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells. Int. J. Cancer124(7), 1594–1604 (2009).
   PubMedGoogle Scholar
• Paschen A, Sucker A, Hill B et al. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin. Cancer Res.15(16), 5208–5215 (2009).
   PubMed Web of Science ®Google Scholar
• Andrés R, Mayordomo JI, Visus C et al. Prognostic significance and diagnostic value of protein S-100 and tyrosinase in patients with malignant melanoma. Am. J. Clin. Oncol.31(4), 335–339 (2008).
   PubMedGoogle Scholar
• Smit LH, Korse CM, Hart AA et al. Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients. Eur. J. Cancer41(3), 386–392 (2005).
   PubMedGoogle Scholar
• Dumitrascu G, Constantin C, Manda G et al. Serum markers in skin melanoma – preliminary study. Roum. Arch. Microbiol. Immunol.69, 41–51 (2009).
   Google Scholar
• Hoek K, Rimm DL, Williams KR et al. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res.64(15), 5270–5282 (2004).
   PubMed Web of Science ®Google Scholar
• Pinnix CC, Lee JT, Liu ZJ et al. Active Notch1 confers a transformed phenotype to primary human melanocytes. Cancer Res.69(13), 5312–5320 (2009).
   PubMed Web of Science ®Google Scholar
• Kang S, Yang C, Luo R. Induction of CCL2 by siMAML1 through upregulation of TweakR in melanoma cells. Biochem. Biophys. Res. Commun.372(4), 629–633 (2008).
   PubMedGoogle Scholar
• Critchley-Thorne RJ, Yan N, Nacu S, Weber J, Holmes SP, Lee PP. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med.4(5), e176 (2007).
   PubMed Web of Science ®Google Scholar
• Wang W, Edington HD, Rao UN et al. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNα2b. Clin. Cancer Res.13(5), 1523–1531 (2007).
   PubMed Web of Science ®Google Scholar
• Varker KA, Kondadasula SV, Go MR et al. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy. Clin. Cancer Res.12(19), 5850–5858 (2006).
   PubMedGoogle Scholar
• Zhao F, Falk C, Osen W, Kato M, Schadendorf D, Umansky V. Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma. Clin. Cancer Res.15(13), 4382–4390 (2009).
   PubMedGoogle Scholar
• Tanase Pistol C, Neagu M, Albulescu R. Key signaling molecules in pituitary tumors. Expert Rev. Mol. Diagn.9(8), 859–877 (2009).
   PubMedGoogle Scholar
• Chien AJ, Moore EC, Lonsdorf AS et al. Activated Wnt/β-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc. Natl Acad. Sci. USA106(4), 1193–1198 (2009).
   PubMed Web of Science ®Google Scholar
• Arenberger P, Arenbergerova M, Vohradnikova O, Kremen J. Early detection of melanoma progression by quantitative real-time RT-PCR analysis for multiple melanoma markers. Keio J. Med.57(1), 57–64 (2008).
   PubMedGoogle Scholar
• Sharma B, Singh S, Varney ML, Singh RK. Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma. Expert Opin. Ther. Targets14(4), 435–442 (2010).
   PubMed Web of Science ®Google Scholar
• Franco R, Cantile M, Scala S et al. Histomorphologic parameters and CXCR4 mRNA and protein expression in sentinel node melanoma metastasis are correlated to clinical outcome. Cancer Biol. Ther.9(6), 423–429 (2010).
   PubMedGoogle Scholar
• Sarff M, Edwards D, Dhungel B et al. OX40 (CD134) expression in sentinel lymph nodes correlates with prognostic features of primary melanomas. Am. J. Surg.195(5), 621–625 (2008).
   PubMed Web of Science ®Google Scholar
• Brennecke S, Deichmann M, Naeher H, Kurzen H. Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma. Melanoma Res.15(6), 515–522 (2005).
   PubMed Web of Science ®Google Scholar
• Varney ML, Johansson SL, Singh RK. Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma. Am. J. Clin. Pathol.125, 209–216 (2006).
   PubMed Web of Science ®Google Scholar
• Schutyser E, Su Y, Yu Y et al. Hypoxia enhances CXCR4 expression in human microvascular endothelial cells and human melanoma cells. Eur. Cytokine Netw.18(2), 59–70 (2007).
   PubMed Web of Science ®Google Scholar
• Guidolin D, Crivellato E, Nico B, Andreis PG, Nussdorfer GG, Ribatti D. An image analysis of the spatial distribution of perivascular mast cells in human melanoma. Int. J. Mol. Med.17(6), 981–987 (2006).
   PubMedGoogle Scholar
• Ch’ng S, Wallis RA, Yuan L, Davis PF, Tan ST. Mast cells and cutaneous malignancies. Mod. Pathol.19(1), 149–159 (2006).
   PubMed Web of Science ®Google Scholar
• Theoharides T, Conti P. Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol.25, 235–241 (2004).
   PubMed Web of Science ®Google Scholar
• Lu C, Kerbel R. Interleukin-6 undergoes transition from a paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J. Cell. Biol.120, 1281–1288 (1993).
   PubMed Web of Science ®Google Scholar
• Redondo P. Update on melanoma: incidence, development and biological aspects. An. Sist. Sanit. Navar.23(1), 67–84 (2000).
   PubMedGoogle Scholar
• Viros A, Fridlyand J, Bauer J et al. Improving melanoma classification by integrating genetic and morphologic features. PLoS Med.5(6), e120 (2008).
   PubMed Web of Science ®Google Scholar
• Ugurel S, Schrama D, Keller G et al. Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy. Cancer Immunol. Immunother.57(5), 685–691 (2008).
   PubMed Web of Science ®Google Scholar
• Takata M, Murata H, Saida T. Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma. Pigment Cell Melanoma Res.23(1), 64–71 (2010).
   PubMedGoogle Scholar
• Jonsson GB, Busch C, Knappskog S et al. Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin. Cancer Res.16(13), 3356–3367 (2010).
   PubMed Web of Science ®Google Scholar
• Woodman SE, Trent JC, Stemke-Hale K et al. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol. Cancer Ther.8(8), 2079–2085 (2009).
   PubMed Web of Science ®Google Scholar
• Su DM, Zhang Q, Wang X et al. Two types of human malignant melanoma cell lines revealed by expression patterns of mitochondrial and survival-apoptosis genes: implications for malignant melanoma therapy. Mol. Cancer Ther.8(5), OF1–OF13 (2009).
   Google Scholar
• Lalou C, Scamuffa N, Mourah S et al. Inhibition of the proprotein convertases represses the invasiveness of human primary melanoma cells with altered p53, CDKN2A and N-Ras genes. PLoS ONE5(4), e9992 (2010).
   Google Scholar
• Zhang H, Sun XF, Synnerstad I, Rosdahl I. Importance of FAS-1377, FAS-670, and FASL-844 polymorphisms in tumor onset, progression, and pigment phenotypes of Swedish patients with melanoma: a case–control analysis. Cancer J.13(4), 233–237 (2007).
   PubMed Web of Science ®Google Scholar
• Philippidou D, Schmitt M, Moser D et al. Signatures of microRNAs and selected microRNA target genes in human melanoma. Cancer Res.70(10), 4163–4173 (2010).
   PubMed Web of Science ®Google Scholar
• Segura MF, Belitskaya-Lévy I, Rose AE et al. Melanoma microRNA signature predicts post-recurrence survival. Clin. Cancer Res.16(5), 1577–1586 (2010).
   PubMed Web of Science ®Google Scholar
• Ribas A. Update on immunotherapy for melanoma J. Natl Compr. Canc. Netw.4(7), 687–694 (2006).
   PubMedGoogle Scholar
• Hsueh EC, Famatiga E, Shu S, Ye X, Morton DL. Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma. Ann. Surg. Oncol.11(10), 892–899 (2004).
   PubMed Web of Science ®Google Scholar
• Gajewski TF. Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. Clin. Cancer Res.12, 2326s–2330s (2006).
   PubMed Web of Science ®Google Scholar
• Schrama D, Hauschild A, Becker JC. Immunmodulatory antibodies in the treatment of skin cancer. Hautarzt59(10), 806–813 (2008).
   PubMedGoogle Scholar
• Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist13(Suppl. 4), 2–9 (2008).
   PubMed Web of Science ®Google Scholar
• Langer LF, Clay TM, Morse MA. Update on anti-CTLA-4 antibodies in clinical trials. Expert Opin. Biol. Ther.7(8), 1245–1256 (2007).
   PubMed Web of Science ®Google Scholar
• Ribas A, Comin-Anduix B, Economou JS et al. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin. Cancer Res.5(1), 390–399 (2009).
   Google Scholar
• Munn DH, Shafizadeh E, Attwood J, Bondarev I, Pashine A, Mellor A. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med.189, 1363–1372 (1999).
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Tarhini AA, Panelli MC et al. Next generation of immunotherapy for melanoma. J. Clin. Oncol.26(20), 3445–3455 (2008).
   PubMed Web of Science ®Google Scholar
• Pashenkov M, Goëss G, Wagner CA et al. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J. Clin. Oncol.24(36), 5716–5724 (2006).
   PubMed Web of Science ®Google Scholar
• Dummer R, Hauschild A, Becker JC et al. An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. Clin. Cancer Res.14(3), 856–864 (2008).
   PubMed Web of Science ®Google Scholar
• Wolf IH, Kodama K, Cerroni L, Kerl H. Nature of inflammatory infiltrate in superficial cutaneous malignancies during topical imiquimod treatment. Am. J. Dermatopathol.29(3), 237–241 (2007).
   PubMedGoogle Scholar
• Delcayre A, Shu H, Le Pecq JB. Dendritic cell-derived exosomes in cancer immunotherapy: exploiting nature’s antigen delivery pathway. Expert Rev. Anticancer Ther.5(3), 537–547 (2005).
   PubMed Web of Science ®Google Scholar
• Hao S, Bai O, Yuan J, Qureshi M, Xiang J. Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes. Cell. Mol. Immunol.3(3), 205–211 (2006).
   PubMed Web of Science ®Google Scholar
• Escudier B, Dorval T, Chaput N et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first Phase I clinical trial. J. Transl. Med.3(1), 10 (2005).
   PubMed Web of Science ®Google Scholar
• Davis ID, Chen Q, Morris L et al. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients. J. Immunother.29(5), 499–511 (2006).
   PubMed Web of Science ®Google Scholar
• Aarntzen EH, Figdor CG, Adema GJ, Punt CJ, de Vries IJ. Dendritic cell vaccination and immune monitoring. Cancer Immunol. Immunother.57(10), 1559–1568 (2008).
   PubMed Web of Science ®Google Scholar
• Mayordomo JI, Andres R, Isla MD et al. Results of a pilot trial of immunotherapy with dendritic cells pulsed with autologous tumor lysates in patients with advanced cancer. Tumori93(1), 26–30 (2007).
   PubMed Web of Science ®Google Scholar
• Nakai N, Katoh N, Germeraad WT et al. Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination. J. Dermatol. Sci.53(1), 40–47 (2009).
   PubMedGoogle Scholar
• van de Ven R, Lindenberg JJ, Oosterhoff D et al. Selective transduction of mature DC in human skin and lymph nodes by CD80/CD86-targeted fiber-modified adenovirus-5/3. J. Immunother.32(9), 895–906 (2009).
   PubMedGoogle Scholar
• Erdmann M, Schuler-Thurner B. Dendritic cell vaccines in metastasized malignant melanoma. G. Ital. Dermatol. Venereol.143(4), 235–250 (2008).
   PubMedGoogle Scholar
• Speiser DE, Pittet MJ, Rimoldi D, Guillaume P, Luescher IF, Liénard D et al. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells. Semin. Cancer Biol.13(6), 461–472 (2003).
   PubMed Web of Science ®Google Scholar
• Chapman PB. Melanoma vaccines. Semin. Oncol.34(6), 516–523 (2007).
   PubMedGoogle Scholar
• Ralph SJ. An update on malignant melanoma vaccine research: insights into mechanisms for improving the design and potency of melanoma therapeutic vaccines. Am. J. Clin. Dermatol.8(3), 123–141 (2007).
   PubMed Web of Science ®Google Scholar
• Slingluff CL Jr, Petroni GR, Olson W et al. Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J. Clin. Oncol.26(30), 4973–4980 (2008).
   PubMed Web of Science ®Google Scholar
• Lienard D, Avril MF, Le Gal FA et al. Vaccination of melanoma patients with Melan-A/Mart-1 peptide and Klebsiella outer membrane protein p40 as an adjuvant. J. Immunother.32(8), 875–878 (2009).
   PubMedGoogle Scholar
• Cesana GC, DeRaffele G, Cohen S et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J. Clin. Oncol.24(7), 1169–1177 (2006).
   PubMed Web of Science ®Google Scholar
• Andersen MH, Gehl J, Reker S et al. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. Semin. Cancer Biol.13(6), 449–459 (2003).
   PubMed Web of Science ®Google Scholar
• Atkins MB. Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin. Cancer Res.12(7 Pt 2), 2353s–2358s (2006).
   Google Scholar
• Varker KA, Kondadasula SV, Go MR et al. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy. Clin. Cancer Res.12(19), 5850–5858 (2006).
   PubMedGoogle Scholar
• Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J, Andreesen R. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J. Clin. Oncol.24(31), 5060–5069 (2006).
   PubMed Web of Science ®Google Scholar
• Green DS, Dalgleish AG, Belonwu N, Fischer MD, Bodman-Smith MD. Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma. Br. J. Dermatol.159(3), 606–614 (2008).
   PubMed Web of Science ®Google Scholar
• Mortarini R, Vegetti C, Molla A et al. Impaired STAT phosphorylation in T cells from melanoma patients in response to IL-2: association with clinical stage. Clin. Cancer Res.15(12), 4085–4094 (2009).
   PubMedGoogle Scholar
• Gerlini G, Mariotti G, Chiarugi A et al. Induction of CD83+CD14+ nondendritic antigen-presenting cells by exposure of monocytes to IFN-α. J. Immunol.181(5), 2999–3008 (2008).
   PubMedGoogle Scholar
• Zimmerer JM, Lesinski GB, Ruppert AS et al. Gene expression profiling reveals similarities between the in vitro and in vivo responses of immune effector cells to IFN-α. Clin. Cancer Res.14(18), 5900–5906 (2008).
   PubMedGoogle Scholar
• Schmidt H, Bastholt L, Geertsen P et al. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br. J. Cancer93(3), 273–278 (2005).
   PubMed Web of Science ®Google Scholar
• Friebe A, Schwarz MJ, Schmid-Wendtner M et al. Pretreatment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-α-induced depressive symptoms in patients with malignant melanoma. J. Immunother.30(3), 333–337 (2007).
   PubMedGoogle Scholar
• Escudier B, Lassau N, Angevin E et al. Phase I trial of sorafenib in combination with IFN α-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin. Cancer Res.13(6), 1801–1809 (2007).
   PubMed Web of Science ®Google Scholar
• Ahmadzadeh M, Antony PA, Rosenberg SA. IL-2 and IL-15 each mediate de novo induction of FOXP3 expression in human tumor antigen-specific CD8 T cells. J. Immunother.30(3), 294–302 (2007).
   PubMed Web of Science ®Google Scholar
• Cocco C, Pistoia V, Airoldi I. New perspectives for melanoma immunotherapy: role of IL-12. Curr. Mol. Med.9(4), 459–469 (2009).
   PubMed Web of Science ®Google Scholar
• Sanchez-Perez L, Kottke T, Daniels GA et al. Killing of normal melanocytes, combined with heat shock protein 70 and CD40L expression, cures large established melanomas. J. Immunol.177(6), 4168–4177 (2006).
   PubMedGoogle Scholar
• Tanase-Pistol C, Raducan E, Dima SO et al. Assessment of soluble angiogenic markers in pancreatic cancer. Biomarkers Med.2(5), 447–455 (2008).
   PubMedGoogle Scholar
• Yang Y, Iyer LK, Adelstein SJ, Kassis AI. Integrative genomic data mining for discovery of potential blood-borne biomarkers for early diagnosis of cancer. PLoS ONE3(11), e3661 (2008).
   PubMedGoogle Scholar
• Weigel MT, Dowsett M. Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr. Relat. Cancer17(4), R245–R262 (2010).
   PubMed Web of Science ®Google Scholar
• Roesch-Ely M, Leipold A, Nees M et al.Proteomic analysis of field cancerization in pharynx and oesophagus: a prospective pilot study. J. Pathol.221(4), 462–470 (2010).
   PubMedGoogle Scholar
• Jennings L, Murphy GM. Predicting outcome in melanoma: where are we now? Br. J. Dermatol.161, 496–503 (2009).
   PubMedGoogle Scholar
• Schiltz PM, Dillman RO. Serum cytokines in metastatic melanoma patients treated with an autologous tumor vaccine. Cancer Biother. Radiopharm.18(6), 879–886 (2003).
   PubMedGoogle Scholar
• Mian S, Ugurel S, Parkinson E et al. Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J. Clin. Oncol.23(22), 5088–5093 (2005).
   PubMed Web of Science ®Google Scholar
• Hofmann MA, Gussmann F, Fritsche A et al. Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma. Melanoma Res.19(1), 17–23 (2009).
   PubMedGoogle Scholar
• O’Day SJ, Maio M, Chiarion-Sileni V et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm Phase II study. Ann. Oncol.21(8), 1712–1717 (2010).
   PubMed Web of Science ®Google Scholar
• Adamina M, Weber WP, Rosenthal R et al. Heterologous prime-boost immunotherapy of melanoma patients with influenza virosomes, and recombinant vaccinia virus encoding 5 melanoma epitopes and 3 co-stimulatory molecules. A multi-centre Phase I/II open labeled clinical trial. Contemp. Clin. Trials29(2), 165–181 (2008).
   PubMedGoogle Scholar
• Jilaveanu LB, Aziz SA, Kluger HM. Chemotherapy and biologic therapies for melanoma: do they work? Clin. Dermatol.27(6), 614–625 (2009).
   PubMed Web of Science ®Google Scholar